Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Could Biosimilar Switchbacks due to ‘Inefficacy’ be Subjective?

Key clinical point: Patient beliefs might influence biosimilar efficacy in rheumatoid arthritis.

Major finding: Ineffectiveness caused 53% of patients to switch from a biosimilar back to an originator product.

Study details: Analysis of data on 760 patients from the British Society for Rheumatology Biologics Register–Rheumatoid Arthritis.

Disclosures: The BSR receives restricted income from multiple U.K. pharmaceutical companies, which is used to fund the BSRBR-RA. The pharmaceutical company funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or any decision to submit manuscripts for publication. The presenters and their teams said they had no competing interests.


Davies R et al. Rheumatology. 2019;58(suppl 3), Abstract 022; and Dahanayake C et al. Rheumatology. 2019;58(suppl 3), Abstract 102.